Patient-support services programs have become common in the pharmaceutical industry and are now considered table stakes for certain disease states. Yet recent government scrutiny has left some pharma companies wondering what to do with these programs in the future.
This POV reviews the current state of affairs and lays out recommendations from overall business, compliance, legal, and regulatory viewpoints. Download it to get the details!